Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Position Increased by Public Sector Pension Investment Board

Key Points

• The Public Sector Pension Investment Board increased its stake in Catalyst Pharmaceuticals, acquiring an additional 131,283 shares, bringing its total holdings to 410,762 shares valued at approximately $9.96 million.
• Insider Preethi Sundaram sold 1,600 shares at an average price of $26.42, resulting in a 3.75% decrease in their position.
• Recent analyst ratings for Catalyst Pharmaceuticals show a mix of opinions, with one upgrade to "strong-buy" and one downgrade to "hold," leading to an overall average rating of "Buy" with a target price of $33.20.

Public Sector Pension Investment Board boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 47.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 410,762 shares of the biopharmaceutical company's stock after purchasing an additional 131,283 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.34% of Catalyst Pharmaceuticals worth $9,961,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $29,000. Sound Income Strategies LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 1st quarter worth about $64,000. GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares during the period. Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $104,000. Finally, New Vernon Capital Holdings II LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 4th quarter worth about $122,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock traded up $0.16 during trading hours on Friday, reaching $20.23. The company had a trading volume of 2,036,554 shares, compared to its average volume of 1,433,487. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.00 and a twelve month high of $26.58. The company has a market capitalization of $2.48 billion, a P/E ratio of 12.26, a price-to-earnings-growth ratio of 0.82 and a beta of 0.70. The stock's fifty day simple moving average is $21.75 and its 200 day simple moving average is $22.69.

Wall Street Analyst Weigh In

CPRX has been the subject of a number of recent research reports. Wall Street Zen lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $33.20.

Insider Buying and Selling

In related news, insider Preethi Sundaram sold 2,324 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total value of $61,376.84. Following the sale, the insider owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. This trade represents a 5.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.